Schott Nexterion AG founded

Activities to date with “uncoated and coated” glass substrates for biochips have been combined under the umbrella Schott Nexterion AG. A new coated glass slide for the immobilization of DNA molecules was already successfully launched into the market a few months ago. A consolidation of these activities together with consistent expansion of the product portfolio along the value-adding chain are planned, including ultimately services for drug discovery and clinical diagnostics. Here, one of the most important core elements will be the use of biochip technologies.
br>In doing so the company will utilize both its own research facilities and look for opportunities to invest in technology partners. At present Schott Nexterion AG has around 40 employees and can take advantage of the world-wide network of the Schott Group for its sales activities.